Innate Pharma eprorts €2.6M Q1 revenue, maintains cash runway to end-Q3 2026

Innate Pharma (NASDAQ:IPHA), a clinical-stage biotechnology company specializing in immuno-oncology, announced its business update and consolidated financial results for the quarter ended March 31, 2026.

Revenue for the three-month period reached €2.6 million, up from €1.2 million in the comparable 2025 period.

The increase was mainly driven by the partial or full recognition of proceeds from collaboration and licensing agreements with AstraZeneca and Sanofi.

As of March 31, 2026, the company held €25.4 million in cash and cash equivalents, with an anticipated cash runway extending until the end of the third quarter of 2026.

Innate noted it is currently negotiating non-dilutive financing options, including pharma partnering and royalty structures.

In its clinical pipeline, the confirmatory Phase 3 TELLOMAK-3 trial of lacutamab in cutaneous T-cell lymphoma (CTCL) remains on track to start in the second half of 2026, subject to securing additional non-dilutive financing.

IPH4502, Innate’s Nectin-4 antibody-drug conjugate (ADC), continues to demonstrate preliminary anti-tumor activity with a favorable safety profile; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion.

The PACIFIC-9 Phase 3 trial of monalizumab, led by AstraZeneca, is progressing toward a planned data readout in the second half of 2026.

Additionally, IPH5201 (anti-CD39 antibody), also in collaboration with AstraZeneca, showed encouraging early clinical results presented at the AACR 2026 Annual Meeting, supporting continued development in the MATISSE Phase 2 study in non-small cell lung cancer (NSCLC).